Perigon Wealth Management LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,548 shares of the company’s stock after selling 674 shares during the quarter. Eli Lilly and Company makes up 0.9% of Perigon Wealth Management LLC’s holdings, making the stock its 17th largest holding. Perigon Wealth Management LLC’s holdings in Eli Lilly and Company were worth $34,152,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in the stock. Capital Planning LLC bought a new position in Eli Lilly and Company during the 1st quarter worth about $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $6,916,000. M&G Plc purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $8,896,000. BTC Capital Management Inc. bought a new position in Eli Lilly and Company in the first quarter worth approximately $1,432,000. Finally, High Net Worth Advisory Group LLC lifted its holdings in Eli Lilly and Company by 1.4% during the first quarter. High Net Worth Advisory Group LLC now owns 4,919 shares of the company’s stock worth $3,827,000 after buying an additional 67 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on LLY shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday. They set an “outperform” rating and a $1,100.00 price objective for the company. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $986.00.
Eli Lilly and Company Price Performance
LLY stock traded up $6.41 during trading on Thursday, hitting $922.83. The stock had a trading volume of 458,889 shares, compared to its average volume of 2,979,211. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company’s 50-day moving average price is $919.25 and its two-hundred day moving average price is $855.84. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $877.06 billion, a P/E ratio of 136.51, a PEG ratio of 2.79 and a beta of 0.42.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
- How to Most Effectively Use the MarketBeat Earnings Screener
- Progressive Leads the Way as Analysts Bet Big on Insurance Stocks
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- NuScale Rockets Higher on Amazon Deal: How High Can It Go?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.